Internal Medicine
Latest news
360 articles · 20 / page
Signaling-Biased Dual GLP-1/GIP Agonist CT-388 Achieves Remarkable 8% Weight Loss in Just Four Weeks
A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in me
Beyond HDL-C: How Macronutrient Shifts Reshape HDL Subspecies to Reduce Coronary Risk
The OmniHeart trial reveals that replacing dietary carbohydrates with unsaturated fats or protein favorably modifies 15 minor protein-based HDL subspecies, shifting the proteomic profile toward lower coronary heart disease risk, independent
Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control
This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic
Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes
A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.
Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes
A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first eviden
Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores
A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul
A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment
This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti
Beyond the Clock: How Circadian Rhythm and Life’s Essential 8 Shape Cardiovascular Longevity
Recent studies from the UK Biobank and Framingham Heart Study reveal that evening chronotypes face higher cardiovascular risks, largely mediated by poor adherence to the Life’s Essential 8 (LE8) health metrics, highlighting the critical rol
Beyond the Dialyzer: The Multidimensional Burden of Chronic Pain in Maintenance Hemodialysis Patients
A cross-sectional analysis of the HOPE Consortium Trial reveals that chronic pain in hemodialysis patients is widespread, frequently musculoskeletal and neuropathic, and strongly associated with psychological and sociodemographic factors ra
Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial
The Study of Drinks with Artificial Sweeteners (SODAS) randomized trial reveals that replacing habitual artificially sweetened beverages with water does not improve HbA1c levels in patients with type 2 diabetes, with the water group surpris
Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial
The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this hig
Beyond the Needle: GRADE Trial Debunks Myths on Insulin Distress and Confirms Adherence as the Glycemic Key
A comprehensive analysis of the GRADE trial substudies reveals that adding basal insulin does not increase emotional distress in early T2DM and highlights the critical, predictive link between medication adherence and long-term glycemic suc
Substantial Residual Risk and High Costs Persist in HFrEF Despite Optimal Quadruple Therapy at Discharge
A nationwide study reveals that HFrEF patients prescribed quadruple therapy at discharge still face a 37% composite risk of death or rehospitalization within one year, with healthcare costs averaging nearly $28,000, highlighting the need fo
Behavioral Science-Integrated EHR Prompts Significantly Increase Deprescribing Rates for Older Adults: A Randomized Clinical Trial
This randomized clinical trial demonstrates that EHR-based behavioral interventions, such as precommitment and boostering prompts, significantly improve deprescribing rates for potentially inappropriate medications in older adults, providin
Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms
A 10-year follow-up of the ASPREE trial reveals that low-dose aspirin does not reduce cancer incidence in adults aged 70 and older, but is associated with increased cancer-related mortality, challenging long-held assumptions about aspirin’s
Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasiz
Beyond the Initial Quit: Mobile Chat Messaging as a Scalable Solution for Smoking Relapse Prevention
Recent clinical trials demonstrate that mobile chat-based interventions, combining live counselors and chatbots, significantly reduce smoking relapse rates and improve long-term abstinence through personalized, real-time support and engagem
Despite Free Devices and Personalized Support, One-Third of Patients Fail to Engage with Home Blood Pressure Monitoring
A retrospective cohort study of 3,390 patients reveals that 32.7% showed zero engagement with home blood pressure monitoring (HBPM) despite receiving free equipment and navigator support, highlighting significant behavioral and procedural b
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
Browse by specialty
Open language-specific specialty feeds and department pages.